Search

Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.

• News
• Retinitis pigmentosa

Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a particular section of the USH2A gene.

• News
• Usher syndrome

Our monthly e-Newsletter featuring the latest updates from Retina UK.

• e-Newsletter
• Audio
• Written

Celebrate the life of your loved one, by donating in their memory and help us fund more research and support, now.

Emily Kearney is mum to four boys, aged four to 13, two of whom are living with an inherited sight loss condition.

• Case study - community
• Written

We have created Discover Wellbeing to help people affected by inherited sight loss to develop an awareness of emotional wellbeing and the practical skills to adapt to life’s ups and downs.

We can provide all the support your organisation needs to work with us; from ideas to practical support and materials. The Retina UK team will help your contribution be as fun and rewarding as possible.

Join our upcoming webinar to hear from our Fundraising manager James Clarke, as he talks to some of our 2025 London Marathon runners!

• Webinar
• Online

Retina UK recently launched an innovative course, Discover Wellbeing, to help those living with inherited sight loss develop an awareness of emotional wellbeing and practical skills to adapt to life’s ups and downs.

• Webinar
• Audio
• Video

A recently published study has described numerous disease mechanisms that appear to be common across different types of inherited sight loss, suggesting that there is significant potential for drug treatments that could work regardless of the underlying causative gene.

• News
• Retinitis pigmentosa